After the update of the American Society of Clinical Oncology and College of American Pathologists guidelines for ERBB2 assessment in BC, a new category named ERBB2-low was proposed.1,3 In this cohort study, our large, unique data set allowed a comprehensive investigation of the epidemiology and the impact of this category in the context of MBC. The gene discussed is ERBB2; the disease is breast cancer.